174 related articles for article (PubMed ID: 37944072)
21.
Heining C; Horak P; Uhrig S; Codo PL; Klink B; Hutter B; Fröhlich M; Bonekamp D; Richter D; Steiger K; Penzel R; Endris V; Ehrenberg KR; Frank S; Kleinheinz K; Toprak UH; Schlesner M; Mandal R; Schulz L; Lambertz H; Fetscher S; Bitzer M; Malek NP; Horger M; Giese NA; Strobel O; Hackert T; Springfeld C; Feuerbach L; Bergmann F; Schröck E; von Kalle C; Weichert W; Scholl C; Ball CR; Stenzinger A; Brors B; Fröhling S; Glimm H
Cancer Discov; 2018 Sep; 8(9):1087-1095. PubMed ID: 29802158
[TBL] [Abstract][Full Text] [Related]
22. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer.
Zhang X; Mao T; Zhang B; Xu H; Cui J; Jiao F; Chen D; Wang Y; Hu J; Xia Q; Ge W; Li S; Yue M; Ma J; Yao J; Wang Y; Wang Y; Shentu D; Zhang X; Chen S; Bai Y; Wang Y; Zhang X; Liu Q; Sun Y; Fu D; Liu Y; Xiong L; Wang L
EBioMedicine; 2022 Mar; 77():103897. PubMed ID: 35231699
[TBL] [Abstract][Full Text] [Related]
24.
Pan M; Jiang C; Zhang Z; Achacoso N; Alexeeff S; Solorzano AV; Tse P; Chung E; Sundaresan T; Suga JM; Thomas S; Habel LA
JCO Precis Oncol; 2023 May; 7():e2200570. PubMed ID: 37163715
[TBL] [Abstract][Full Text] [Related]
25. Molecular characterisation of pancreatic ductal adenocarcinoma with
Allen MJ; Zhang A; Bavi P; Kim JC; Jang GH; Kelly D; Perera S; Denroche RE; Notta F; Wilson JM; Dodd A; Ramotar S; Hutchinson S; Fischer SE; Grant RC; Gallinger S; Knox JJ; O'Kane GM
J Clin Pathol; 2023 Mar; 76(3):158-165. PubMed ID: 34583947
[TBL] [Abstract][Full Text] [Related]
26. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
Datta J; Bianchi A; De Castro Silva I; Deshpande NU; Cao LL; Mehra S; Singh S; Rafie C; Sun X; Chen X; Dai X; Colaprico A; Sharma P; Dosch AR; Pillai A; Hosein PJ; Nagathihalli NS; Komanduri KV; Wilson JM; Ban Y; Merchant NB
Oncogene; 2022 Jul; 41(28):3640-3654. PubMed ID: 35701533
[TBL] [Abstract][Full Text] [Related]
27. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
Reissig TM; Tzianopoulos I; Liffers ST; Rosery VK; Guyot M; Ting S; Wiesweg M; Kasper S; Meister P; Herold T; Schmidt HH; Schumacher B; Albers D; Markus P; Treckmann J; Schuler M; Schildhaus HU; Siveke JT
ESMO Open; 2023 Jun; 8(3):101539. PubMed ID: 37148593
[TBL] [Abstract][Full Text] [Related]
28. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A
Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294
[TBL] [Abstract][Full Text] [Related]
29. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma.
Deshpande V; Konstantinidis IT; Castillo CF; Hezel AF; Haigis KM; Ting DT; Bardeesy N; Goyal L; Zhu AX; Warshaw AL; Lillemoe KD; Ferrone CR
J Gastrointest Surg; 2016 May; 20(5):953-9. PubMed ID: 26956004
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract][Full Text] [Related]
31. Treatment patterns and survival in patients with early-onset pancreatic cancer.
Saadat LV; Chou JF; Gonen M; Soares KC; Kingham TP; Varghese AM; Jarnagin WR; D'Angelica MI; Drebin JA; O'Reilly EM; Wei AC
Cancer; 2021 Oct; 127(19):3566-3578. PubMed ID: 34228820
[TBL] [Abstract][Full Text] [Related]
32.
Jones MR; Williamson LM; Topham JT; Lee MKC; Goytain A; Ho J; Denroche RE; Jang G; Pleasance E; Shen Y; Karasinska JM; McGhie JP; Gill S; Lim HJ; Moore MJ; Wong HL; Ng T; Yip S; Zhang W; Sadeghi S; Reisle C; Mungall AJ; Mungall KL; Moore RA; Ma Y; Knox JJ; Gallinger S; Laskin J; Marra MA; Schaeffer DF; Jones SJM; Renouf DJ
Clin Cancer Res; 2019 Aug; 25(15):4674-4681. PubMed ID: 31068372
[TBL] [Abstract][Full Text] [Related]
33. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
34. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
35. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
[TBL] [Abstract][Full Text] [Related]
36. Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study.
Yang F; He Y; Ge N; Guo J; Yang F; Sun S
Front Immunol; 2023; 14():1203459. PubMed ID: 38268915
[TBL] [Abstract][Full Text] [Related]
37. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
Luchini C; Paolino G; Mattiolo P; Piredda ML; Cavaliere A; Gaule M; Melisi D; Salvia R; Malleo G; Shin JI; Cargnin S; Terrazzino S; Lawlor RT; Milella M; Scarpa A
J Exp Clin Cancer Res; 2020 Oct; 39(1):227. PubMed ID: 33115526
[TBL] [Abstract][Full Text] [Related]
38. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.
Krasinskas AM; Chiosea SI; Pal T; Dacic S
Mod Pathol; 2014 Feb; 27(2):262-70. PubMed ID: 23887294
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.
Moser R; Annis J; Nikolova O; Whatcott C; Gurley K; Mendez E; Moran-Jones K; Dorrell C; Sears RC; Kuo C; Han H; Biankin A; Grandori C; Von Hoff DD; Kemp CJ
Cancer Res; 2022 Sep; 82(18):3375-3393. PubMed ID: 35819261
[TBL] [Abstract][Full Text] [Related]
40. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
